Dr.SurgeonPGH said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
Compounded has been just as effective for me. If compounded supply is the concern, the COA from my 503B pharmacy shows 99.1% purity. Verified by Janoshik.
One thing that is still open after PharmHunterJen’s answer:
What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?
quinn_sf said:Compounded has been just as effective for me.
Coming at quinn_sf’s question from a different direction. The trade-off is reversibility against privacy and there is no option that gives you both. Card payments are reversible and disclose the most; crypto discloses least and is irreversible, which is precisely why pressure toward it is a warning sign when it comes from a seller rather than a buyer. Escrow only means anything where the escrow agent is independent of both parties, which is rarely the case in practice.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsClosing the loop on my own question.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.
sean_dublin said:The trade-off is reversibility against privacy and there is no option that gives you both.
Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.